RefleXion Medical has successfully treated its inaugural cancer patient using SCINTIX biology-guided radiotherapy at Stanford Medicine Cancer Center. SCINTIX therapy, a radiopharmaceutical-driven approach, tailors treatment based on tumor biology. This milestone marks autonomous radiotherapy’s debut, reflecting years of effort. FDA-cleared for lung and bone tumors, SCINTIX shows potential in managing tumor motion. The CEO hails it as a breakthrough in treating metastatic disease. Multiple US cancer centers will adopt SCINTIX, extending its availability by end 2023. SCINTIX uniquely targets and treats solid tumors, advancing external-beam radiotherapy capabilities.
RefleXion Medical, a pioneering oncology company, has officially announced the successful treatment completion of the inaugural patient utilizing SCINTIX biology-guided radiotherapy on the cutting-edge RefleXion X1 machine situated at the Stanford Medicine Cancer Center. This groundbreaking SCINTIX therapy represents a revolutionary radiopharmaceutical-guided approach to treating both early and late-stage cancers. The technique leverages the unique biological characteristics of each tumor to orchestrate its own therapeutic regimen.
The achievement of delivering SCINTIX therapy at Stanford Medicine marks a pivotal moment in healthcare, introducing the era of autonomous radiotherapy. Dr. Sam Mazin, the founder and Chief Technology Officer of RefleXion, expressed immense satisfaction, stating, “The debut of SCINTIX treatment at Stanford Medicine signifies the advent of autonomous radiotherapy, and we’re profoundly delighted. This significant milestone has been the culmination of over a decade of dedicated effort. On behalf of the entire RefleXion team, I extend my gratitude to our early adopter clinical sites, valued advisors, and investors who have collaborated with us in realizing and launching this novel treatment option catering to patients across various stages of solid tumor conditions.”
FDA clearance has been granted for SCINTIX biology-guided radiotherapy to address patients grappling with lung and bone tumors, encompassing cases originating from primary cancers or metastatic formations stemming from other parts of the body. The therapeutic potential of SCINTIX therapy in precisely managing tumor movement led to its designation as a Breakthrough Device for lung tumor treatment.
Todd Powell, the CEO of RefleXion, expressed the significance of this achievement, remarking, “The commencement of SCINTIX treatment signifies a monumental moment for both medical professionals and patients. At last, we possess a technology that holds the promise of effectively combatting metastatic disease. As clinical understanding and practice guidelines increasingly emphasize the importance of treating all observable disease in specific cancers, SCINTIX was conceptualized with this objective in mind. It complements pharmacological interventions to enhance outcomes, particularly for individuals contending with advanced-stage cancers.”
In the upcoming weeks, esteemed cancer centers across the United States, including the City of Hope Comprehensive Cancer Center in Southern California, facilities in Pennsylvania and Texas, will initiate the administration of SCINTIX therapy. By the culmination of 2023, SCINTIX therapy will extend its availability to New Jersey, Connecticut, and Oregon.
Overcoming the challenges tied to target precision and motion management, particularly for multiple tumors, is the foremost hurdle impeding the efficiency of external-beam radiotherapy in metastatic cancer treatment. SCINTIX therapy ingeniously employs emissions originating from cancer cells, induced by the introduction of a radiopharmaceutical into the patient’s system. This approach facilitates the continual and autonomous delivery of targeted radiation to the cancerous tissue. Additionally, this innovative capability concurrently illuminates all identified cancer targets within the body during treatment. Distinguishing itself, the X1 featuring SCINTIX stands as the world’s sole dual-treatment modality radiotherapy platform capable of addressing patients affected by solid tumors at various stages.
